Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms

被引:1
作者
Hu, Huihui [1 ]
Zhao, Jin [1 ]
Yuan, Judong [1 ]
Zhang, Man [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Clin Lab, 10 Tieyi Rd, Beijing 100038, Peoples R China
[2] Beijing Key Lab Urinary Cellular Mol Diagnost, Beijing, Peoples R China
[3] Peking Univ, Clin Lab Med, Sch Clin Med 9, Beijing 100038, Peoples R China
关键词
PD-1; Tim-3; Peritoneal neoplasms; Primary sites; Pathological types; Progression-free survival; Flow cytometry; T-CELL EXHAUSTION; NIVOLUMAB; CANCER; IMMUNOTHERAPY; BIOMARKERS; EXPRESSION; BLOCKADE;
D O I
10.1186/s12885-023-10752-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeProgrammed death-1 (PD-1) and T cell immunoglobulin and mucin-domain-containing molecule 3(Tim-3) may be used as the biomarkers for the therapy in patients with peritoneal neoplasms. In the current study, the differential percentages of peripheral PD-1 and Tim-3 are explored to investigate whether to associate with primary sites and pathological types of patients with peritoneal neoplasms or not. We also investigated the frequencies of PD-1 and Tim-3 on circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells if would correlate with the progression-free survival of peritoneal neoplasms patients.Methods115 patients with peritoneal neoplasms were recruited, subjected to multicolor flow cytometric analyses of the percentages of PD-1 and Tim-3 receptors of circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells. The peritoneal neoplasms patients were divided into primary group and secondary group depending on whether the tumor had primary focus and limited to peritoneal tumor or not. Then all the patients were regrouped by the pathological types of neoplasms (adenocarcinoma, mesothelioma, and pseudomyxoma). The secondary peritoneal neoplasms group was divided into the different primary site groups (colon, gastric, gynecology). This study also enrolled 38 cases of normal volunteers. The above markers were explored by flow cytometer, to find the differential levels in peritoneal neoplasms patients compared with normal group in peripheral blood.ResultsHigher levels of CD4 + T lymphocytes, CD8 + T lymphocytes, CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, CD3 + CD4 + PD-1 + T cells, CD3 + CD8 + PD-1 + T cells and CD45 + Tim-3 + lymphocytes were found in peritoneal neoplasms group than normal control (the p value was respectively 0.004, 0.047, 0.046, 0.044, 0.014, 0.038 and 0.017). Compared with primary peritoneal neoplasms group, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, and CD3 + CD4 + PD-1 + T cells were increased in the secondary peritoneal neoplasms group (the p value was respectively 0.010, 0.044, and 0.040), while PD-1 did not correlate with the primary sites in secondary group (P > 0.05). Tim-3 had no statistical differences in primary peritoneal neoplasms group compared with secondary group (p > 0.05), but CD45 + Tim-3+% lymphocytes, CD3 + Tim-3+%T cells, and CD3 + CD4 + Tim-3 + T cells were associated with different secondary sites of peritoneal neoplasms (p < 0.05). In the different pathological type groups, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells presented the higher levels in adenocarcinoma group compared with mesothelioma group (p = 0.048, p = 0.045). The frequencies of CD45 + PD-1 + lymphocytes and CD3 + PD-1 + T cells in peripheral blood were associated with progression-free survival (PFS).ConclusionsOur work uncovers peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. Those findings might provide important assessment to predict peritoneal neoplasms patients' immunotherapy responses.
引用
收藏
页数:11
相关论文
共 30 条
  • [1] Tim-3 finds its place in the cancer immunotherapy landscape
    Acharya, Nandini
    Sabatos-Peyton, Catherine
    Anderson, Ana Carrizosa
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [2] Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
    Auer, Katharina
    Bachmayr-Heyda, Anna
    Sukhbaatar, Nyamdelger
    Aust, Stefanie
    Schmetterer, Klaus G.
    Meier, Samuel M.
    Gerner, Christopher
    Grimm, Christoph
    Horvat, Reinhard
    Pils, Dietmar
    [J]. ONCOTARGET, 2016, 7 (38) : 61336 - 61354
  • [3] Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer
    Baba, Y.
    Yagi, T.
    Kosumi, K.
    Okadome, K.
    Nomoto, D.
    Eto, K.
    Hiyoshi, Y.
    Nagai, Y.
    Ishimoto, T.
    Iwatsuki, M.
    Iwagami, S.
    Miyamoto, Y.
    Yoshida, N.
    Komohara, Y.
    Watanabe, M.
    Baba, H.
    [J]. BRITISH JOURNAL OF SURGERY, 2019, 106 (10) : 1352 - 1361
  • [4] PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
    Bekos, Christine
    Pils, Dietmar
    Dekan, Sabine
    Hofstetter, Gerda
    Horak, Peter
    Reinthaller, Alexander
    Polterauer, Stephan
    Schwameis, Richard
    Aust, Stefanie
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
    Bellmunt, Joaquin
    Powles, Thomas
    Vogelzang, Nicholas J.
    [J]. CANCER TREATMENT REVIEWS, 2017, 54 : 58 - 67
  • [6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [8] Targeting T Cell Co-receptors for Cancer Therapy
    Callahan, Margaret K.
    Postow, Michael A.
    Wolchok, Jedd D.
    [J]. IMMUNITY, 2016, 44 (05) : 1069 - 1078
  • [9] Induction and transcriptional regulation of the co-inhibitory gene module in T cells
    Chihara, Norio
    Madi, Asaf
    Kondo, Takaaki
    Zhang, Huiyuan
    Acharya, Nandini
    Singer, Meromit
    Nyman, Jackson
    Marjanovic, Nemanja D.
    Kowalczyk, Monika S.
    Wang, Chao
    Kurtulus, Sema
    Law, Travis
    Etminan, Yasaman
    Nevin, James
    Buckley, Christopher D.
    Burkett, Patrick R.
    Buenrostro, Jason D.
    Rozenblatt-Rosen, Orit
    Anderson, Ana C.
    Regev, Aviv
    Kuchroo, Vijay K.
    [J]. NATURE, 2018, 558 (7710) : 454 - +
  • [10] Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Drake, Charles G.
    Kluger, Harriet
    Stadler, Walter M.
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan
    Harrison, Michael R.
    Plimack, Elizabeth R.
    Appleman, Leonard
    Fong, Lawrence
    Albiges, Laurence
    Cohen, Lewis
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Kurland, John F.
    Simon, Jason S.
    Sznol, Mario
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5461 - 5471